Concert Pharmaceuticals, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CNCE
  • 1d0.12%
  • 1w0.00%
  • 1m0.48%
  • 1y193.68%
ATH
  • ATH Price$29.05
  • ATH Date2017-12-19
  • % since ATH-71.19%
  • % to ATH247.07%
ATL
  • ATL Price$2.69
  • ATL Date2021-10-22
  • % from ATL211.15%
  • Last Low Price$2.69
  • Last Low Date2021-10-22
  • % From Last Low211.15%
IPO
  • IPO Price$15.75
  • % Current ROI USD-46.86%
  • ATH Price$29.05
  • % ROI ATH 107,992.57%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CNCE"]

Key Data [addtoany]

Current price $8.37
Sector Healthcare
Industry Biotechnology
Today's High/Low $8.37/$8.37
Volume 0.00
Previous Close $8.36
52 Week High/Low $8.55/$2.66
Market Cap 401,949,152.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-2.69
Annualized Dividend $0
$8.37
[addtoany]

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition.
Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Annual Data | Millions of US $ except per share data 2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Cash on hand $111.81$160.84$203.17$96.19$142.19----
Receivables $0.07$0.02$0.16$0.03$0.25$1.28---
Inventory --$0$0$0$0---
Pre-Paid Expenses ---------
Other Current Assets $4.71$18.74$0$0$1.67$1.21$1.11$1.18$0.85
Total Current Assets $116.86$180.15$205.73$97.73$144.11$81.72---
Property, Plant, And Equipment $17.01$8.92$2.17$2.20$2.35$2.28$2.47$3.45$4.44
Long-Term Investments $2.36$2.32$2.25------
Goodwill And Intangible Assets --$0$0$0$0---
Other Long-Term Assets $3.61$3.48$3.84$0.47$0.48$0.45$3.26$0.83$0.83
Total Long-Term Assets $20.62$12.40$6$2.67$2.82----
Total Assets $137.47$192.55$211.74$100.40$146.93$84.45$39.77$33.13$49.40
Total Current Liabilities $17.27$8.75$6.45$5.57$6.63$18.62$15.92$7.91$10.27
Long Term Debt --$0$0$0$0$7.35$15.50$8.05
Other Non-Current Liabilities $2.75$16.06$8.86$9.23$9.67$11.01$16.37$4.56$6.34
Total Long Term Liabilities $18.75$16.06$8.86$9.23$9.67----
Total Liabilities $36.01$24.81$15.30$14.80$16.30$29.63$39.63$27.97$24.66
Common Stock Net $0.02$0.02$0.02$0.02$0.02$0.02$0100000$0100000$0100000
Retained Earnings (Accumulated Deficit) $-194.68$-116.52$-76.24$-171.88$-121.16$-145.34---
Comprehensive Income --$0$0$0$0---
Other Share Holders Equity $-0.03$-0.14$-0.41$-0700000$-0.02$-0.01---
Share Holder Equity $101.46$167.74$196.43$85.59$130.64$54.83$0.14$5.16$24.74
Total Liabilities And Share Holders Equity $137.47$192.55$211.74$100.40$146.93----